Common Sense Health: Fighting cancer with precision

By Diana Gifford-Jones on April 2, 2026.

In my work with universities, I meet an array of Canada’s leading researchers. This week, it was Arghya Paul, Canada Research Chair in the Department of Chemical and Biochemical Engineering and Chemistry at Western University in London, Ontario. Professor Paul and his team of young researchers are investigating new ways to fight cancer.

For decades, the war on cancer has relied on chemotherapy and radiation to kill cancer cells, treatments that often harm healthy cells too.

Now, scientists like Paul are exploring smarter ways to deploy drugs. He is working not at the scale of the tumour or the cancerous lesion, but at the bio-molecular level of the nanoscale. That’s one billionth of a metre, where materials can be engineered to interact with the body in highly specific ways.

Instead of flooding the body with toxic chemicals, researchers are designing tiny biocompatible particles that travel through the bloodstream, seek out cancer cells, and act only where needed. It is a guided system rather than a scattershot approach. These particles can be activated by ultrasound waves. When exposed to a specific ultrasound intensity, they heat up and destroy tumour cells from within. Healthy cells nearby are largely spared.

Additionally, these particles can track tumour sites in the body using advanced clinical imaging systems. That means they can do more than one job at a time. They help doctors both see cancer cells more clearly and site-specifically destroy them. Detection and treatment are part of the same process.

This is a big shift in thinking. For years, medicine has treated diagnosis and therapy as separate steps. First find the disease. Then treat it. Now, the two are beginning to merge.

As Professor Paul explains, “This research represents a shift from treating cancer with blunt tools to engineering precise responses at the microscopic level. We’re beginning to program how therapeutic agents should interact with cancer cells rather than simply attacking them.”

His research lab is looking into how these systems can be built to respond to the unique environment of a tumour. Cancer cells often differ from normal cells in subtle ways. They may have slightly more acidic surroundings, different oxygen levels, or altered surface markers. Nanoparticles can be engineered to recognize these differences and act only when they are encountered.

The goal is simple in concept, but revolutionary in practice: maximum damage to cancer, minimal harm to the patient.

There is still a long road ahead. Much of this work is in experimental stages. What works in a laboratory dish or in animal studies does not always translate to human patients. Safety, long-term effects, and large-scale manufacturing are all challenges that must be overcome.

But the direction is clear. We are moving away from a model of medicine that relies on broadly toxic interventions, and toward one emphasizing precision, personalization, and control. This could mean fewer side effects, shorter recovery periods, and more effective treatments.

It could also mean catching and eliminating cancers earlier, before they have a chance to spread.

What’s another important insight? The future of medicine will not come from biology alone. It will come from the merging of physics, engineering, chemistry, and medicine. We need to stop thinking about doctors solely as people who come out of medical schools. The lifesavers may be graduates of engineering programs in advanced materials.

We are not yet at the point where cancer can be treated without risk or discomfort. But we are closer to a world where treatment is targeted, intelligent, and far less destructive, using microscopic tools designed with extraordinary precision, aimed directly at the disease, and nowhere else.

Carry on, researchers!

This column offers opinions on health and wellness, not personal medical advice. Visit http://www.docgiff.com to learn more. For comments, diana@docgiff.com. Follow on Instagram @diana_gifford_jones

17
-16